IRIS
BIANCONI, MARISTELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.832
EU - Europa 912
AS - Asia 280
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 1
Totale 3.046
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.832
IT - Italia 241
UA - Ucraina 192
SE - Svezia 120
IE - Irlanda 105
TR - Turchia 99
DE - Germania 86
CN - Cina 81
DK - Danimarca 75
FI - Finlandia 53
SG - Singapore 49
KR - Corea 41
GB - Regno Unito 23
CI - Costa d'Avorio 14
IN - India 9
BE - Belgio 8
FR - Francia 5
EU - Europa 4
DZ - Algeria 3
NL - Olanda 2
BR - Brasile 1
CZ - Repubblica Ceca 1
RS - Serbia 1
VN - Vietnam 1
Totale 3.046
Salva come PNG Salva come JPEG
Città #
Chandler 236
Fairfield 217
Jacksonville 206
Wilmington 136
Ashburn 108
Dublin 105
Centro 96
Seattle 95
Woodbridge 83
Houston 73
Ann Arbor 69
New York 62
Cambridge 59
Boardman 51
Des Moines 51
Lawrence 43
Princeton 43
San Mateo 43
Turin 43
Beijing 19
San Diego 17
Helsinki 15
Abidjan 14
Pune 9
Brussels 8
Izmir 8
Singapore 8
London 7
Cagliari 6
Los Angeles 6
Norwalk 6
Shanghai 6
Wuxi 6
Kilburn 5
Washington 5
Wuhan 5
Guangzhou 4
Jiaxing 3
New Bedfont 3
Amantea 2
Amsterdam 2
Chicago 2
Clifton 2
Como 2
Fayetteville 2
Florence 2
Jinhua 2
Marche 2
Milan 2
Modena 2
Montesilvano 2
Porto 2
Prescot 2
Rome 2
Roseto degli Abruzzi 2
Scafati 2
Venice 2
Acton 1
Ascoli Piceno 1
Belgrade 1
Berlin 1
Brasília 1
Chiswick 1
Chizhou 1
Civitanova Marche 1
Cupra Marittima 1
Dalian 1
Dong Ket 1
Dongyang 1
Foshan 1
Frankfurt (Oder) 1
Hanover 1
Hounslow 1
Islington 1
Matelica 1
Nantong 1
Olomouc 1
Pesaro 1
Qingdao 1
San Francisco 1
San Giuliano 1
Santa Clara 1
Seoul 1
Simi Valley 1
Stamford 1
Suzhou 1
Tiantai Chengguanzhen 1
Torre Del Greco 1
Xuzhou 1
Yiwu 1
Totale 2.048
Salva come PNG Salva come JPEG
Nome #
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 127
Immunotherapy in genitourinary cancers: Where are we going? 116
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 115
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 112
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 99
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 94
Adjuvant treatment after surgical resection 86
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 84
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. 84
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 82
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 82
Il profilo angiogenico nel carcinoma renale metastatico: implicazioni prognostiche e terapeutiche 82
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 80
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 80
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 78
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 78
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 77
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 77
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 77
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 76
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 75
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 74
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 72
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 72
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 66
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 66
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 66
Panitumumab for the treatment of metastatic colorectal cancer: A review 65
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 65
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 63
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 61
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 61
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 57
Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. 54
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 54
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 54
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 53
The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? 53
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 53
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 52
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma 48
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma 39
State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. 33
Totale 3.142
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.628
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.628
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020244 0 0 36 3 42 0 41 7 41 5 12 57
2020/2021769 47 71 82 4 126 74 70 48 54 100 64 29
2021/2022370 35 92 4 5 2 19 21 22 18 53 29 70
2022/2023727 53 98 59 48 47 114 1 38 166 3 83 17
2023/2024364 61 2 29 45 54 93 6 11 1 6 8 48
2024/202571 71 0 0 0 0 0 0 0 0 0 0 0
Totale 3.142